Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
6 Months : From Apr 2019 to Oct 2019
By Michael Dabaie
Lexicon Pharmaceuticals Inc. (LXRX) was up 7.2% to $6.39 in heavier-than-average trading Monday.
The company said Friday that the European Commission granted marketing authorization for Zynquista, which was developed by Sanofi (SNY) and Lexicon. Zynquista is now approved in the European Union for treatment of adults with type 1 diabetes.
Lexicon said Zynquista also is currently being evaluated in a program of 11 clinical trials in adults with type 2 diabetes, including two trials in people living with type 2 diabetes and renal impairment, and two large cardiovascular outcomes trials.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
April 29, 2019 11:25 ET (15:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.